Status:
UNKNOWN
Methylene Blue in Severe Sepsis and Septic Shock
Lead Sponsor:
Seoul National University Hospital
Conditions:
Severe Sepsis
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is to see whether the intravenous administration of methylene blue improves the outcome in severe sepsis and septic shock.
Detailed Description
The mortality of septic shock is still high ranging from 30 to 50%. Vasopressor is the main part in managing septic shock, but the choice of vasopressor is still under-investigated, and area of uncert...
Eligibility Criteria
Inclusion
- Septic shock meeting the criteria of 2012 surviving sepsis campaign
- Need the norepinephrine of over 0.2microgram/kg/min
Exclusion
- Pregnancy
- Less than 18 years old
- Terminal cancer patients
- Declined consents
- glucose-6-phosphate dehydrogenase deficiency
- Medication of Serotonin modulator
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2017
Estimated Enrollment :
354 Patients enrolled
Trial Details
Trial ID
NCT01797978
Start Date
February 1 2013
End Date
March 1 2017
Last Update
November 18 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Kyeongi-do, South Korea
2
Seoul National University Hospital
Seoul, South Korea
3
SMG - SNU Boramae Medical Center
Seoul, South Korea